95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Jin Li1,2†
Xu Zhang3,4*†Liuke Yang5Youwei Zhu6Rongrong Gao7Tiancheng Zhang3,4Xuwen Chen8Jun Fu9Gaoyang He9Huijuan Shi3,4Shenjie Peng10XiaoHua Wu1,2*- 1Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China
- 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- 3NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai, China
- 4Shanghai-MOST Key Laboratory of Health and Disease Genomics, NHC Key Lab of Reproduction Regulation, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai, China
- 5College of plant protection, Nanjing Agricultural University, Nanjing, China
- 6Clinical Center of Bio-Therapy at Zhongshan Hospital & Institutes of Biomedical Sciences, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China
- 7Clinical Center for Biotherapy at Zhongshan Hospital, Fudan University, Shanghai, China
- 8Shanghai Kelin Clinical Bioinformatics Institute, Shanghai, China
- 9LC-Bio Technology Co., Ltd, Hangzhou, China
- 10Fudan University, Shanghai, China
by Zhang X, Li J, Yang L, Zhu Y, Gao R, Zhang T, Chen X, Fu J, He G, Shi H, Peng S and Wu X (2024). Front. Immunol. 15:1391524. doi: 10.3389/fimmu.2024.1391524
In the published article, there was an error in affiliation 1, 2, 3, 4. Instead of “1NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai, China
2Shanghai-MOST Key Laboratory of Health and Disease Genomics, NHC Key Lab of Reproduction Regulation, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai, China
3Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China
4Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China”, it should be “1Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China
2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
3NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai, China
4Shanghai-MOST Key Laboratory of Health and Disease Genomics, NHC Key Lab of Reproduction Regulation, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai 20037, China”.
In the published article, there was an error in the author list, and the first two authors appeared in the wrong order. The corrected author list appears below.
Jin Li1,2,†, Xu Zhang3,4,†,*, Liuke Yang5, Youwei Zhu6, Rongrong Gao7, Tiancheng Zhang3,4, Xuwen Chen8, Jun Fu9, Gaoyang He9, Huijuan Shi3,4, Shenjie Peng10, XiaoHua Wu1,2,*.
In the published article, there was an error of incorrect representation of the name of the ethics committee and errors in the choice between work email and personal email of co-correspondence author.
A correction has been made to Ethics statement and correspondence section. This sentence previously stated:
“The studies involving humans were approved by the ethics committee of Fudan University Cancer Hospital Shanghai, China.”
XiaoHua WueGh3dTIzMTNAMTYzLmNvbQ==
The corrected sentence appears below:
“The studies involving human participants were reviewed and approved by Ethics Committee of Fudan University Shanghai Cancer Center (approval number: 050432-4-1805C).”
XiaoHua Wud3UueGhAZnVkYW4uZWR1LmNu
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: cervical cancer, biomarker, proteomics, prognosis, immunotherapy response
Citation: Li J, Zhang X, Yang L, Zhu Y, Gao R, Zhang T, Chen X, Fu J, He G, Shi H, Peng S and Wu X (2024) Corrigendum: Targeted proteomics-determined multi-biomarker profiles developed classifier for prognosis and immunotherapy responses of advanced cervical cancer. Front. Immunol. 15:1437676. doi: 10.3389/fimmu.2024.1437676
Received: 24 May 2024; Accepted: 18 June 2024;
Published: 02 July 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Li, Zhang, Yang, Zhu, Gao, Zhang, Chen, Fu, He, Shi, Peng and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xu Zhang, emhhbmd4dTU5MjBAb3V0bG9vay5jb20=; XiaoHua Wu, d3UueGhAZnVkYW4uZWR1LmNu
†These authors have contributed equally to this work